BIOMAT Database Logo BIOMAT Database Logo

Somatostatin-like immunoreactivity in CSF in schizophrenic patients during haloperidol treatment. 1992

J Jolkkonen, and A Pitkänen, and P J Riekkinen, and E R Korpi, and C A Kaufmann, and D R Weinberger
Vaajasalo Hospital, Kortejoki, Kuopio, Finland.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010455 Peptides Members of the class of compounds composed of AMINO ACIDS joined together by peptide bonds between adjacent amino acids into linear, branched or cyclical structures. OLIGOPEPTIDES are composed of approximately 2-12 amino acids. Polypeptides are composed of approximately 13 or more amino acids. PROTEINS are considered to be larger versions of peptides that can form into complex structures such as ENZYMES and RECEPTORS. Peptide,Polypeptide,Polypeptides
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D005260 Female Females
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder

Related Publications

J Jolkkonen, and A Pitkänen, and P J Riekkinen, and E R Korpi, and C A Kaufmann, and D R Weinberger
Effects of haloperidol on somatostatin-like immunoreactivity in the CSF of Schizophrenic patients.
January 1986, Psychiatry research,
J Jolkkonen, and A Pitkänen, and P J Riekkinen, and E R Korpi, and C A Kaufmann, and D R Weinberger
CSF somatostatin-like immunoreactivity in dementia.
February 1986, Neurology,
J Jolkkonen, and A Pitkänen, and P J Riekkinen, and E R Korpi, and C A Kaufmann, and D R Weinberger
CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease.
December 1990, Journal of neurology, neurosurgery, and psychiatry,
J Jolkkonen, and A Pitkänen, and P J Riekkinen, and E R Korpi, and C A Kaufmann, and D R Weinberger
Somatostatin-like immunoreactivity in the CSF of patients with dementia associated with alcoholism.
November 1990, Acta neurologica Scandinavica,
J Jolkkonen, and A Pitkänen, and P J Riekkinen, and E R Korpi, and C A Kaufmann, and D R Weinberger
Long-term treatment with carbamazepine affects CSF somatostatin immunoreactivity in epileptic patients.
January 1992, Acta neurologica,
J Jolkkonen, and A Pitkänen, and P J Riekkinen, and E R Korpi, and C A Kaufmann, and D R Weinberger
Decreased somatostatin-like immunoreactivity in the cerebrospinal fluid of chronic schizophrenic patients with cognitive impairment.
September 1990, Psychiatry research,
J Jolkkonen, and A Pitkänen, and P J Riekkinen, and E R Korpi, and C A Kaufmann, and D R Weinberger
Carbamazepine lowering effect on CSF somatostatin-like immunoreactivity in temporal lobe epileptics.
August 1986, Acta neurologica Scandinavica,
J Jolkkonen, and A Pitkänen, and P J Riekkinen, and E R Korpi, and C A Kaufmann, and D R Weinberger
Lower CSF level of dynorphin(1-8) immunoreactivity in schizophrenic patients.
February 1985, Neuropeptides,
J Jolkkonen, and A Pitkänen, and P J Riekkinen, and E R Korpi, and C A Kaufmann, and D R Weinberger
Effects of haloperidol on CSF glutamate levels in drug-naive schizophrenic patients.
July 1995, Schizophrenia research,
J Jolkkonen, and A Pitkänen, and P J Riekkinen, and E R Korpi, and C A Kaufmann, and D R Weinberger
Somatostatin-like immunoreactivity and substance-P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus.
January 1985, Journal of neurology,
Copied contents to your clipboard!